India to tackle global obesity with cheap fat-loss jabsIndia's weight-loss drug sales are projected to soar to over half a billion by 2030. (Photo: AFP)MUMBAI — A deluge of weight‑loss drugs is set to transform the global fight against obesity as India prepares to unleash low‑cost generic versions of injections like Ozempic after a key patent expired Friday. By the end of 2026, core patents on semaglutide will have expired in 10 countries that represent 48% of the global obesity burden, according to a study published earlier this month by researchers. At least four major firms have already prepared generic semaglutide injections, regulatory filings and compliance documents viewed by AFP show. India's weight‑loss drug sales have grown tenfold in five years to US$153 million as of 2026, and are projected to soar to over half a billion by 2030.

Source: Bangkok Post March 20, 2026 11:43 UTC